Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure

R. Grose, J. Strain, Mark A. Greenberg, T. H. LeJemtel

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

The effects of dobutamine and intravenous milrinone on systemic hemodynamics, coronary blood flow and myocardial metabolism were studied in 11 patients with severe congestive heart failure. Although milrinone and dobutamine similarly increased cardiac index from 1.9 ± 0.4 to 2.5 ± 0.4 liters/min per m2 (p < 0.001) and from 1.9 ± 0.4 to 2.8 ± 0.8 liters/min per m2 (p < 0.001), respectively, milrinone decreased left ventricular end-diastolic pressure to a greater extent than dobutamine, that is, from 26 ± 6 to 12 ± 8 mm Hg (p < 0.001) versus 26 ± 8 to 20 ± 8 mm Hg (p < 0.001). In contrast to dobutamine, milrinone significantly reduced mean systemic arterial and right atrial pressures. Dobutamine increased the first derivative of left ventricular pressure (dP/dt) from 1,013 ± 309 to 1,360 ± 538 mm Hg/s (p < 0.01) but milrinone die not. Similarly, blood flow and myocardial oxygen consumption were increased by dobutamine from 152 ± 87 to 187 ± 118 ml/min (p < 0.05) and from 17.7 ± 10.9 to 21.5 ± 14.9 ml O2/min (p < 0.05), respectively, but were unchanged by milrinone. Both drugs significantly decreased coronary vascular resistance and myocardial oxygen extraction but did not change myocardial lactate extraction. Thus, dobutamine and milrinone produce similar improvement in cardiac index. However, dobutamine increases myocardial oxygen consumption, whereas milrinone does not. This difference can probably be explained by the substantial vasodilating properties of milrinone.

Original languageEnglish (US)
Pages (from-to)1107-1113
Number of pages7
JournalJournal of the American College of Cardiology
Volume7
Issue number5
StatePublished - 1986

Fingerprint

Milrinone
Dobutamine
Heart Failure
Oxygen Consumption
Atrial Pressure
Ventricular Pressure
Vascular Resistance
Lactic Acid
Hemodynamics
Oxygen
Blood Pressure

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. / Grose, R.; Strain, J.; Greenberg, Mark A.; LeJemtel, T. H.

In: Journal of the American College of Cardiology, Vol. 7, No. 5, 1986, p. 1107-1113.

Research output: Contribution to journalArticle

@article{87368194497945938fe4dc18221cf068,
title = "Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure",
abstract = "The effects of dobutamine and intravenous milrinone on systemic hemodynamics, coronary blood flow and myocardial metabolism were studied in 11 patients with severe congestive heart failure. Although milrinone and dobutamine similarly increased cardiac index from 1.9 ± 0.4 to 2.5 ± 0.4 liters/min per m2 (p < 0.001) and from 1.9 ± 0.4 to 2.8 ± 0.8 liters/min per m2 (p < 0.001), respectively, milrinone decreased left ventricular end-diastolic pressure to a greater extent than dobutamine, that is, from 26 ± 6 to 12 ± 8 mm Hg (p < 0.001) versus 26 ± 8 to 20 ± 8 mm Hg (p < 0.001). In contrast to dobutamine, milrinone significantly reduced mean systemic arterial and right atrial pressures. Dobutamine increased the first derivative of left ventricular pressure (dP/dt) from 1,013 ± 309 to 1,360 ± 538 mm Hg/s (p < 0.01) but milrinone die not. Similarly, blood flow and myocardial oxygen consumption were increased by dobutamine from 152 ± 87 to 187 ± 118 ml/min (p < 0.05) and from 17.7 ± 10.9 to 21.5 ± 14.9 ml O2/min (p < 0.05), respectively, but were unchanged by milrinone. Both drugs significantly decreased coronary vascular resistance and myocardial oxygen extraction but did not change myocardial lactate extraction. Thus, dobutamine and milrinone produce similar improvement in cardiac index. However, dobutamine increases myocardial oxygen consumption, whereas milrinone does not. This difference can probably be explained by the substantial vasodilating properties of milrinone.",
author = "R. Grose and J. Strain and Greenberg, {Mark A.} and LeJemtel, {T. H.}",
year = "1986",
language = "English (US)",
volume = "7",
pages = "1107--1113",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure

AU - Grose, R.

AU - Strain, J.

AU - Greenberg, Mark A.

AU - LeJemtel, T. H.

PY - 1986

Y1 - 1986

N2 - The effects of dobutamine and intravenous milrinone on systemic hemodynamics, coronary blood flow and myocardial metabolism were studied in 11 patients with severe congestive heart failure. Although milrinone and dobutamine similarly increased cardiac index from 1.9 ± 0.4 to 2.5 ± 0.4 liters/min per m2 (p < 0.001) and from 1.9 ± 0.4 to 2.8 ± 0.8 liters/min per m2 (p < 0.001), respectively, milrinone decreased left ventricular end-diastolic pressure to a greater extent than dobutamine, that is, from 26 ± 6 to 12 ± 8 mm Hg (p < 0.001) versus 26 ± 8 to 20 ± 8 mm Hg (p < 0.001). In contrast to dobutamine, milrinone significantly reduced mean systemic arterial and right atrial pressures. Dobutamine increased the first derivative of left ventricular pressure (dP/dt) from 1,013 ± 309 to 1,360 ± 538 mm Hg/s (p < 0.01) but milrinone die not. Similarly, blood flow and myocardial oxygen consumption were increased by dobutamine from 152 ± 87 to 187 ± 118 ml/min (p < 0.05) and from 17.7 ± 10.9 to 21.5 ± 14.9 ml O2/min (p < 0.05), respectively, but were unchanged by milrinone. Both drugs significantly decreased coronary vascular resistance and myocardial oxygen extraction but did not change myocardial lactate extraction. Thus, dobutamine and milrinone produce similar improvement in cardiac index. However, dobutamine increases myocardial oxygen consumption, whereas milrinone does not. This difference can probably be explained by the substantial vasodilating properties of milrinone.

AB - The effects of dobutamine and intravenous milrinone on systemic hemodynamics, coronary blood flow and myocardial metabolism were studied in 11 patients with severe congestive heart failure. Although milrinone and dobutamine similarly increased cardiac index from 1.9 ± 0.4 to 2.5 ± 0.4 liters/min per m2 (p < 0.001) and from 1.9 ± 0.4 to 2.8 ± 0.8 liters/min per m2 (p < 0.001), respectively, milrinone decreased left ventricular end-diastolic pressure to a greater extent than dobutamine, that is, from 26 ± 6 to 12 ± 8 mm Hg (p < 0.001) versus 26 ± 8 to 20 ± 8 mm Hg (p < 0.001). In contrast to dobutamine, milrinone significantly reduced mean systemic arterial and right atrial pressures. Dobutamine increased the first derivative of left ventricular pressure (dP/dt) from 1,013 ± 309 to 1,360 ± 538 mm Hg/s (p < 0.01) but milrinone die not. Similarly, blood flow and myocardial oxygen consumption were increased by dobutamine from 152 ± 87 to 187 ± 118 ml/min (p < 0.05) and from 17.7 ± 10.9 to 21.5 ± 14.9 ml O2/min (p < 0.05), respectively, but were unchanged by milrinone. Both drugs significantly decreased coronary vascular resistance and myocardial oxygen extraction but did not change myocardial lactate extraction. Thus, dobutamine and milrinone produce similar improvement in cardiac index. However, dobutamine increases myocardial oxygen consumption, whereas milrinone does not. This difference can probably be explained by the substantial vasodilating properties of milrinone.

UR - http://www.scopus.com/inward/record.url?scp=0022577626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022577626&partnerID=8YFLogxK

M3 - Article

C2 - 3958369

AN - SCOPUS:0022577626

VL - 7

SP - 1107

EP - 1113

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 5

ER -